RegeneRx Biopharmaceuticals announced the outcome of discussions between its U.S. joint venture, ReGenTree LLC, and the FDA regarding the results of the completed phase 3 clinical trial (ARISE-2) and the future development requirements for a new drug application submission of RGN-259, a novel drug candidate to treat dry eye syndrome.
"Although the FDA is requiring an additional phase 3 trial (ARISE-3) to further demonstrate efficacy in both signs and symptoms of dry eye in a larger patient population, all safety data from ARISE-1 and ARISE-2 were accepted by the FDA, no additional nonclinical efficacy and safety studies are required by the FDA, and the company's chemistry and manufacturing control plans for the drug substance and drug product were considered complete and acceptable for NDA submission. ReGenTree is now planning to initiate the ARISE-3 trial this year," Won Yang, ReGenTree's president and chief executive officer, said in a company news release.
"We are pleased that we are moving forward with development of RGN-259 for dry eye and that our partner has effectively completed the comprehensive and expensive ancillary work required for an NDA, including the numerous toxicology, stability and manufacturing studies required to bring a new drug to the market," stated J.J. Finkelstein, RegeneRx's president and chief executive officer.
The ReGenTree team will attend the upcoming ARVO (The Association for Research in Vision and Ophthalmology) 2018 annual meeting to be held on April 29-May 3 in the U.S. to work with key opinion leaders as well as meet with potential strategic partners.